RU320521 | CAS#2262452-06-0 | RU.521 | cGAS inhibitor

MedKoo Cat#: 555738 | Name: RU320521

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RU320521, also known as RU.521, is a potent and selective inhibitor of cGAS, inhibiting cGAS-mediated signaling, being active in murine bone marrow-derived macrophage.

Chemical Structure

RU320521

CAS#2262452-06-0

Theoretical Analysis

MedKoo Cat#: 555738

Name: RU320521

CAS#: 2262452-06-0

Chemical Formula: C19H12Cl2N4O3

Exact Mass: 414.0286

Molecular Weight: 415.23

Elemental Analysis: C, 54.96; H, 2.91; Cl, 17.07; N, 13.49; O, 11.56

Price and Availability

Size	Price	Availability
5mg	USD 150.00	Ready to ship
10mg	USD 250.00	Ready to ship
25mg	USD 450.00	Ready to ship
50mg	USD 750.00	Ready to ship
100mg	USD 1,350.00	Ready to ship
200mg	USD 2,350.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

RU320521; RU-320521; RU 320521; RU521; RU-521; RU 521; RU.521;

IUPAC/Chemical Name

3-[1-(6,7-Dichloro-1H-benzimidazol-2-yl)-5-hydroxy-3-methyl-pyrazol-4-yl]-3H-isobenzofuran-1-one

InChi Key

VIQXILLOJLATEF-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H12Cl2N4O3/c1-8-13(16-9-4-2-3-5-10(9)18(27)28-16)17(26)25(24-8)19-22-12-7-6-11(20)14(21)15(12)23-19/h2-7,16,26H,1H3,(H,22,23)

SMILES Code

O=C1OC(C2=C(O)N(C3=NC4=CC=C(Cl)C(Cl)=C4N3)N=C2C)C5=C1C=CC=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and ethanol

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A21T09K06

QC Data

View QC data: current batch, Lot#A21T09K06

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

RU320521 inhibits the cGAS-mediated signaling with IC50 of 700 nM. RU.521 binds to the cGAS/dsDNA complex with Kd of 36.2 nM.

In vitro activity:

RU320521 is capable of potently and selectively inhibiting mouse and human cGAS in cell lines and human primary cells. When RU320521 is applied to cells, the production of dsDNA-induced intracellular cGAMP is suppressed in a dose-dependent manner. This work validates the use of RU320521 for probing DNA-induced innate immune responses and underscores its potential as an ideal scaffold towards pre-clinical development, given its potency against human and mouse cGAS. Reference: Sci Rep. 2020 May 5;10(1):7604. https://pubmed.ncbi.nlm.nih.gov/32371942/

In vivo activity:

RU320521 was investigated in a study focused on trauma-induced delayed bone healing. In C57BL/6 J mice, RU320521 reduced IFNβ levels in bronchioalveolar fluid at 24 hours. RU320521 administration immediately after injury led to improved bone healing. These data reveal that the cGAS-STING signaling pathway influences trauma-induced delayed bone healing. Reference: J Exp Orthop. 2023 Sep 1;10(1):90. https://pubmed.ncbi.nlm.nih.gov/37656236/

	Solvent	mg/mL	mM
Solubility
	DMSO	83.0	199.89
	Ethanol	2.0	4.82

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 415.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wiser C, Kim B, Vincent J, Ascano M. Small molecule inhibition of human cGAS reduces total cGAMP output and cytokine expression in cells. Sci Rep. 2020 May 5;10(1):7604. doi: 10.1038/s41598-020-64348-y. PMID: 32371942; PMCID: PMC7200739. 2. Muire PJ, Lofgren AL, Shiels SM, Wenke JC. Fracture healing in a polytrauma rat model is influenced by mtDNA:cGAS complex mediated pro-inflammation. J Exp Orthop. 2023 Sep 1;10(1):90. doi: 10.1186/s40634-023-00637-5. PMID: 37656236. 3. Jiang Z, Jiang Y, Fan J, Zhang J, Xu G, Fan Y, Zhang L, Qin X, Jiang X, Mao L, Liu G, Chen C, Zou Z. Inhibition of cGAS ameliorates acute lung injury triggered by zinc oxide nanoparticles. Toxicol Lett. 2023 Jan 15;373:62-75. doi: 10.1016/j.toxlet.2022.11.002. Epub 2022 Nov 8. PMID: 36368621.

In vitro protocol:

In vivo protocol:

1. Muire PJ, Lofgren AL, Shiels SM, Wenke JC. Fracture healing in a polytrauma rat model is influenced by mtDNA:cGAS complex mediated pro-inflammation. J Exp Orthop. 2023 Sep 1;10(1):90. doi: 10.1186/s40634-023-00637-5. PMID: 37656236. 2. Jiang Z, Jiang Y, Fan J, Zhang J, Xu G, Fan Y, Zhang L, Qin X, Jiang X, Mao L, Liu G, Chen C, Zou Z. Inhibition of cGAS ameliorates acute lung injury triggered by zinc oxide nanoparticles. Toxicol Lett. 2023 Jan 15;373:62-75. doi: 10.1016/j.toxlet.2022.11.002. Epub 2022 Nov 8. PMID: 36368621.

1: Inoue K, Ishizawa M, Kubota T. Monoclonal anti-dsDNA antibody 2C10 escorts DNA to intracellular DNA sensors in normal mononuclear cells and stimulates secretion of multiple cytokines implicated in lupus pathogenesis. Clin Exp Immunol. 2020 Feb;199(2):150-162. doi: 10.1111/cei.13382. Epub 2019 Oct 29. PMID: 31604370; PMCID: PMC6954677. 2: Xie W, Lama L, Adura C, Tomita D, Glickman JF, Tuschl T, Patel DJ. Human cGAS catalytic domain has an additional DNA-binding interface that enhances enzymatic activity and liquid-phase condensation. Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11946-11955. doi: 10.1073/pnas.1905013116. Epub 2019 May 29. PMID: 31142647; PMCID: PMC6575157. 3: Zhou W, Whiteley AT, de Oliveira Mann CC, Morehouse BR, Nowak RP, Fischer ES, Gray NS, Mekalanos JJ, Kranzusch PJ. Structure of the Human cGAS-DNA Complex Reveals Enhanced Control of Immune Surveillance. Cell. 2018 Jul 12;174(2):300-311.e11. doi: 10.1016/j.cell.2018.06.026. PMID: 30007416; PMCID: PMC6084792. 4: Vincent J, Adura C, Gao P, Luz A, Lama L, Asano Y, Okamoto R, Imaeda T, Aida J, Rothamel K, Gogakos T, Steinberg J, Reasoner S, Aso K, Tuschl T, Patel DJ, Glickman JF, Ascano M. Publisher Correction: Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nat Commun. 2017 Nov 23;8(1):1827. doi: 10.1038/s41467-017-01770-3. Erratum for: Nat Commun. 2017 Sep 29;8(1):750. PMID: 29170402; PMCID: PMC5700994. 5: Vincent J, Adura C, Gao P, Luz A, Lama L, Asano Y, Okamoto R, Imaeda T, Aida J, Rothamel K, Gogakos T, Steinberg J, Reasoner S, Aso K, Tuschl T, Patel DJ, Glickman JF, Ascano M. Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nat Commun. 2017 Sep 29;8(1):750. doi: 10.1038/s41467-017-00833-9. Erratum in: Nat Commun. 2017 Nov 23;8(1):1827. PMID: 28963528; PMCID: PMC5622107.